Novo Nordisk’s dominance in the obesity drug market was challenged when the company reported disappointing results for their new obesity drug, CagriSema. The drug led patients to lose 20% of their weight in a late-stage study, falling short of the company’s projection of 25% weight loss. This news caused Novo’s stock to drop by nearly 18%. Investors had high hopes for CagriSema, which combines semaglutide and cagrilintide. The results raise concerns about Novo’s ability to replicate the success of their blockbuster drugs, Ozempic and Wegovy. This development may impact Novo Nordisk’s position in the obesity drug market.
Source link
What Novo Nordisk’s disappointing trial results mean for the obesity drug market
